Skip to main content

Beta Bionics, Inc.

BBNX
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001674632

In the last 90 days, Beta Bionics, Inc. insiders filed 0 open-market purchases and 12 sales; 133 institutions reported holding it in 13F filings for Q2 2026, worth $752.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Beta Bionics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
12 filings
6 insiders, $2.50M in total
Insiders trading
6
Net value
−$2.50M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Beta Bionics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Beta Bionics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Jones ChristyDirector19,564Sep 23, 20265
Hopman MarkChief Commercial Officer88,033Sep 18, 202610
Mensinger MikeChief Product Officer177,390Sep 17, 20267
Saint SeanPresident & CEO398,429Sep 4, 20265
Russell Steven JonChief Medical Officer169,628Sep 3, 20264
Feider StephenChief Financial Officer159,378Sep 3, 20268
Michel Gerard JDirector33,509May 26, 20262
Carney SeanDirector32,209May 26, 20262
Dearen Danny L.Director32,209May 26, 20262
Palasis MariaDirector29,397May 26, 20264
Lezack AdamDirector27,399May 26, 20264
Wellington Hadley Harbor Aggregator IV, L.P.10% Owner3,901,599Feb 3, 20250

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 25, 2026 (view filing)Jun 241 dayHopman MarkChief Commercial OfficerSSale−1.26K$15.01−$18.9K−1.0%129.4K after10b5-1
Jul 2, 2026 (view filing)6:44 PM ETJun 26-296 daysFeider StephenChief Financial OfficerSSale−10.0K$17.04−$170.4K−5.7%166.1K afterAmended2 lots10b5-1
Sep 3, 2026 (view filing)6:15 PM ETSep 21 daySaint SeanPresident & CEOSSale−16.9K$19.11−$322.4K−4.0%404.1K after
Sep 3, 2026 (view filing)6:15 PM ETSep 21 dayFeider StephenChief Financial OfficerSSale−6.67K$19.11−$127.6K−4.0%159.4K after
Sep 3, 2026 (view filing)6:15 PM ETSep 21 dayMensinger MikeChief Product OfficerSSale−4.38K$19.11−$83.6K−2.4%180.0K after
Sep 3, 2026 (view filing)6:15 PM ETSep 21 dayRussell Steven JonChief Medical OfficerSSale−4.22K$19.11−$80.7K−2.4%169.6K after
Sep 3, 2026 (view filing)6:15 PM ETSep 21 dayHopman MarkChief Commercial OfficerSSale−5.33K$19.11−$101.8K−4.1%124.0K after
Sep 4, 2026 (view filing)5:19 PM ETSep 31 daySaint SeanPresident & CEOSSale−5.64K$20.08−$113.3K−1.4%398.4K after10b5-1
Sep 15, 2026 (view filing)4:15 PM ETSep 141 dayHopman MarkChief Commercial OfficerSSale−775$15.52−$12.0K−0.9%86.4K after10b5-1
Sep 17, 2026 (view filing)4:15 PM ETSep 161 dayMensinger MikeChief Product OfficerSSale−2.65K$22.00−$58.3K−1.5%177.4K after10b5-1
Sep 17, 2026 (view filing)4:15 PM ETSep 161 dayHopman MarkChief Commercial OfficerSSale−30.8K$20.13−$619.6K−35.3%56.5K after10b5-1
Sep 18, 2026 (view filing)7:51 PM ETSep 99 daysHopman MarkChief Commercial OfficerSSale−36.0K$18.46−$664.6K−29.0%88.0K afterAmended10b5-1
Sep 23, 2026 (view filing)5:40 PM ETSep 221 dayJones ChristyDirectorSSale−6.43K$23.00−$147.9K−24.7%19.6K after10b5-1